Light gray square, with a dark gray border on the sides.

Blog

The Role of CT Plaque Analysis in Clinical Decision-Making

May 26, 2026

In cases where the clinical picture alone is insufficient to guide treatment, CT plaque analysis serves as a powerful tie-breaker — moving the decision from population-level risk estimates to a direct assessment of what is occurring inside an individual patient's arteries.



When results reveal no significant plaque, this provides objective evidence that the patient's arterial health is better than their risk factors alone might suggest. This finding can reasonably support a decision to defer or withhold statin therapy, while offering meaningful reassurance to both the patient and their clinician. 

Conversely, when results demonstrate a high plaque burden or high-risk plaque features, this confirms that atherosclerotic disease is already silently progressing — even in the absence of symptoms. Such findings justify initiating or intensifying statin therapy and often prompt a broader, more aggressive approach to cardiovascular risk factor management.

It is within this decision-making framework that the clinical indications for CT plaque analysis are best understood.



CT plaque analysis (typically performed as part of coronary CT angiography (CCTA) with plaque characterization) is indicated in the following clinical scenarios:

Primary Cardiovascular Risk Assessment

  • Patients with intermediate pre-test probability based on their symptoms, age, sex, and risk factors of coronary artery disease (CAD) where risk stratification would change management

  • Asymptomatic patients with an intermediate Atherosclerotic Cardiovascular Disease (ASCVD) risk score (7.5–20%) in whom a treatment decision (e.g., statin initiation) is uncertain. The Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score is a calculation that estimates a patient's 10-year risk of having a major cardiovascular event.

INPUT EXAMPLE
Age & Sex Older age and male sex increase risk
Race Affects baseline risk calculation
Total Cholesterol & LDL Higher = more risk
HDL Cholesterol Lower = more risk
Blood Pressure Higher = more risk
Diabetes Presence increases risk
Smoking Status Current smoker = higher risk
BP Treatment Status Whether on antihypertensives
  • Adjunct to or replacement for a coronary artery calcium (CAC) score when more detailed plaque morphology is needed The CAC score only sees calcified plaque — plaque that has already hardened with calcium deposits.


    It completely misses:

    • Soft plaque (lipid-rich, non-calcified plaque)
    • Mixed plaque (partially calcified)
    • Vulnerable/high-risk plaque features that are most likely to rupture and cause a heart attack

This is critically important because:


The plaques most likely to cause a heart attack are often the soft, non-calcified ones — not the hard, calcified ones

Calcified plaque is more stable in many cases. It's the soft, lipid-rich plaques that are prone to rupturing, triggering a clot, and causing an acute myocardial infarction.

Symptomatic Patients

  • Stable chest pain or anginal equivalents with low-to-intermediate pre-test probability of obstructive CAD

  • Atypical chest pain where non-invasive functional testing is inconclusive

  • Dyspnea of unclear etiology where cardiac cause needs to be excluded

High-Risk Plaque Detection


Identifying vulnerable/high-risk plaque features that predict future acute coronary syndrome (ACS), such as:


  • Low-attenuation plaque (lipid-rich necrotic core)
  • Positive remodeling
  • Napkin-ring sign
  • Spotty calcification

Post-Treatment Monitoring

  • Assessing plaque regression or stabilization in response to statin or PCSK9 inhibitor therapy

  • Surveillance in patients with known non-obstructive CAD to track plaque burden progression

Specific Patient Populations

  • Diabetes mellitus with atypical or silent ischemia presentations

  • Chronic kidney disease patients in whom stress testing is limited

  • Young patients with premature atherosclerosis or familial hypercholesterolemia

  • Competitive athletes with exertional symptoms

  • Patients with discordant risk (e.g., elevated LDL but low CAC score, or vice versa)

  • Pre-operative evaluation in selected patients before major non-cardiac surgery

Acute/Urgent Settings

  • Acute chest pain in the emergency department with low-to-intermediate HEART score (as part of the Triple Rule-Out protocol or focused CCTA)

  • Differentiating ACS from non-cardiac causes of chest pain

Contraindications to Consider


CT plaque analysis is generally not indicated in:

  • Patients with known obstructive CAD (invasive coronary angiography preferred)
  • Very high or very low pre-test probability (low diagnostic yield)
  • Severe renal impairment (contrast contraindicated)
  • Significant arrhythmia (poor image quality)
  • Inability to achieve adequate heart rate control

A Simple Analogy


Think of coronary arteries like a pipe:

  • A CAC score is like checking if there is rust (calcium) visible on the outside of the pipe
  • CT plaque analysis is like doing a full internal inspection - checking for rust, soft buildup, weak spots, and areas about to crack



The CAC score tells you something is there. CT plaque analysis tells you what it is, how dangerous it is, and where exactly the risk lies. CT plaque analysis is the step up when you need to truly understand the nature and danger of what is building up inside a patient's coronary arteries.

A PRACTICAL EXAMPLE

A 58-year-old man, no symptoms, has high cholesterol, is borderline hypertensive, and smokes occasionally. His ASCVD score comes back at 14% - intermediate risk.



Should he start a statin?


On paper, it's unclear. But if a CT plaque analysis reveals:


  • Heavyplaque burden with low-attenuation (vulnerable) plaques → Start statin, possibly refer to cardiology
  • No plaque detected → May defer statin, focus on lifestyle, recheck in a tew years

Note: Guidelines from the ACC/AHA, ESC, and SCCT continue to evolve regarding optimal patient selection. Shared decision-making between clinician and patient is central to appropriate ordering, particularly for asymptomatic individuals.

Team collaborating in a green control room with monitors, charts, and people discussing documents.
October 12, 2026
Part 4 of 6 in Circle CVI's Structural Heart series. Every Scan. One Plan. One Platform. Structural heart programs get measured on procedure volume. Case counts, room utilization, length of stay, the board slide with the line going up.  None of that is where the queue forms. Every structural referral begins with a CT and a heart-team decision, and both of those happen in imaging. When referral volume rises, the cath lab feels it second.
Person at a desk measuring cardiac anatomy on a large monitor in a green workspace
October 10, 2026
Part 3 of 6 in Circle CVI's Structural Heart series. Every Scan. One Plan. One Platform. Ask who plans a structural heart case and you will usually hear the name of a physician. Ask what the plan is made of and you arrive somewhere else: a centralized 3D lab, a queue of studies covering three different procedures, and an analyst doing the measurement work that everyone downstream treats as fact.  That work is the most standardized thing in the structural program and the least discussed.
Person at a cardiac workstation reviewing screens with green-themed interface and data visuals
October 6, 2026
Part 2 of 6 in Circle CVI's Structural Heart series. Every Scan. One Plan. One Platform. A diagnostic cardiac CT report ends in an impression. A structural planning report ends in a set of numbers that a heart team will use to select a device. That is a different product. The impression tolerates hedging, because the clinician reading it brings their own judgment to the question. The planning report does not, because a millimeter of annulus perimeter is not an opinion to be weighed. It is an input to a sizing chart. Imaging physicians have absorbed this shift largely without anyone naming it.
Two people in lab coats discuss a heart scan on a monitor in a green-toned medical office.
September 29, 2026
Part 1 of 6 in Circle CVI's Structural Heart series. Every Scan. One Plan. One Platform. The annulus measurement decides the case. Valve choice follows from it. So does sizing, so does the degree of oversizing, so does whether the root tolerates that oversizing, and so does whether you spend the end of an otherwise clean case managing a paravalvular leak. By the time the patient is on the table, that measurement was made days earlier, in a post-processing application the operator may never open, by a reader whose work arrives as a number on a report.  For a procedure this dependent on millimeters, that is worth examining.

Subscribe to our newsletter

 Don’t miss future articles or publications.